Mallinckrodt PLC

Mallinckrodt Plc engages in the development, manufacture, market, adn distribution of both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes innovative specialty pharmaceutical brands. The Specialty Generics segment relates to niche specialty generic drugs and active pharmaceutical ingredients. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The company filed a lawsuit to stop a federal decision that could be very bad news for its top drug.

Why Mallinckrodt Stock Is Tanking Today

Mallinckrodt Plc shares MNK, -11.24% fell 10% in premarket trade Tuesday after the drug company said it has filed suit against the U.S.

UPDATE: Mallinckrodt stock slides 10% premarket after it files suit over Medicaid patient access to Acthar gel

Lannett Company

Mylan

Teva Pharmaceutical

Forty-four states have brought a lawsuit against the industry.

Here's Why Generic-Drug Manufacturers Were Down Monday

Mallinckrodt (MNK) earnings and sales surpass estimates in the first quarter, which led to an increase in annual guidance.

Mallinckrodt (MNK) Beats on Q1 Earnings & Sales, Raises View

Mallinckrodt plc (MNK) CEO Mark Trudeau on Q1 2019 Results - Earnings Call Transcript

Mallinckrodt Pharmaceuticals soared in premarket trading Tuesday after the company released first-quarter earnings that beat Wall Street's expectations and raised its profit outlook for the year.

Mallinckrodt jumps 9% after beating first-quarter earnings estimates, raises 2019 profit outlook

Mallinckrodt (MNK) delivered earnings and revenue surprises of 12.14% and 2.47%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Mallinckrodt (MNK) Surpasses Q1 Earnings and Revenue Estimates

Shares of Mallinckrodt PLC  shot up 13% in premarket trade Tuesday, after the drug maker reported first-quarter earnings and sales that beat expectations.

Mallinckrodt's stock soars after profit and sales beat, raised guidance

Investors are looking forward to the performance of Specialty Brands and other pipeline updates, when Mallinckrodt (MNK) reports Q1 results on May 7.

Is a Beat in the Cards for Mallinckrodt (MNK) Q1 Earnings?

In the latest trading session, Mallinckrodt (MNK) closed at $15.29, marking a -1.1% move from the previous day.

Mallinckrodt (MNK) Dips More Than Broader Markets: What You Should Know

Diebold Nixdorf Inc

Texas Roadhouse

Poor earnings and other business threats hurt these stocks.

Why Diebold Nixdorf, Mallinckrodt, and Texas Roadhouse Slumped Today

Mallinckrodt (MNK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mallinckrodt (MNK) Earnings Expected to Grow: Should You Buy?

Amphastar Pharma

MNK vs. AMPH: Which Stock Is the Better Value Option?

MNK or AMPH: Which Is the Better Value Stock Right Now?

Bank of New York Mellon

Downbeat news from several sources hurt these stocks.

Why Sprint, Bank of New York Mellon, and Mallinckrodt Slumped Today

Mallinckrodt (MNK) closed the most recent trading day at $21.66, moving -0.18% from the previous trading session.

Mallinckrodt (MNK) Stock Sinks As Market Gains: What You Should Know

Mallinckrodt (MNK) ends enrollment in the phase III study on StrataGraft, a regenerative skin tissue used in patients with thermal burns.

Mallinckrodt (MNK) Completes Enrollment in Skin Tissue Study

Management has delivered on guidance and debt reduction.

Mallinckrodt: One-Year Review

Is  (MNK) Outperforming Other Medical Stocks This Year?

Has Mallinckrodt public limited (MNK) Outpaced Other Medical Stocks This Year?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Mallinckrodt (MNK) Stock Undervalued Right Now?

Mallinckrodt (MNK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Mallinckrodt (MNK) Down 12.1% Since Last Earnings Report?

Mallinckrodt (MNK) closed the most recent trading day at $21.51, moving +0.61% from the previous trading session.

Mallinckrodt (MNK) Gains As Market Dips: What You Should Know

MNK vs. AMPH: Which Stock Should Value Investors Buy Now?

Is Mallinckrodt public limited (MNK) Stock Outpacing Its Medical Peers This Year?

Mallinckrodt (MNK) closed the most recent trading day at $23.80, moving +0.59% from the previous trading session.

News for Mallinckrodt PLC Stock (MNK)